Belite Bio (Belite Bio) ROCE % : -34.67% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Belite Bio ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Belite Bio's annualized ROCE % for the quarter that ended in Mar. 2024 was -34.67%.

Belite Bio ROCE % Historical Data

The historical data trend for Belite Bio's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belite Bio ROCE % Chart

Belite Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

-23.14

-46.60

-42.91

-47.45

Belite Bio Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial							-67.14	-54.69	-74.13	-37.06	-34.67

Belite Bio ROCE % Calculation

Belite Bio's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-31.598	/	( ( (44.273 - 2.104)	+	(94.642 - 3.633) )	/ 2 )
	=	-31.598	/	( (42.169	+	91.009)	/ 2 )
	=	-31.598	/	66.589
	=	-47.45 %

Belite Bio's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-33.312	/	( ( (94.642 - 3.633)	+	(101.147 - 0) )	/ 2 )
	=	-33.312	/	( ( 91.009	+	101.147 )	/ 2 )
	=	-33.312	/	96.078
	=	-34.67 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Belite Bio (NAS:BLTE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Belite Bio ROCE % Related Terms

Thank you for viewing the detailed overview of Belite Bio's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Belite Bio (Belite Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Belite Bio Inc (NAS:BLTE) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130

Website

https://www.belitebio.com

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.